Will AI create more assets than pharma can absorb? AI is often discussed as a solution to pharmaceutical research and development productivity. It may be. Certainly Big Pharma thinks so,…
After ~six months of integrating AI into our workflows at Lacerta Bio (plus building a few custom tools for ourselves and our clients), I've developed what I call the "intern-to-partner…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Ownership and Inventorship Ambiguity Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those…
Experts predict that 2026 will bring mixed outcomes in the industry, with caution in investment approaches dominating trends. Concerns about safety versus innovation persist alongside debates on licensing versus M&A. Execution quality is emphasized as crucial, potentially overshadowing compelling scientific narratives. Uncertainty remains about strategic effectiveness in navigating upcoming challenges.
In every industry, revenue is driven by a simple equation: Revenue = (Price per Unit) × (Units Sold) For most sectors, both levers are available. A company can raise prices,…
Poor Louie... Poor Louie King Louis XI of France (1423-1483) was an interesting character. At 17, he rebelled against his Father, Charles VII. Later forgiven by papa, he ascended to the…
I. Introduction In our industry, not all companies are built for, or even aspire to, worldwide reach. Many are geographically limited, with commercial operations confined to a single country (such…
Introduction One of the benefits of having BIO in Boston is that it provides me with a ~3.5 hour drive back to New York. This gives me a chance to…
https://youtu.be/ryfz4zM6RJA Our Annual Year in Review Video - 2024 Edition At long last, here is our Annual Year in Review video - 2024 Edition. In this video, we cover: FDA…